



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/692206/2011

European Medicines Agency decision P/220/2011

of 30 September 2011

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for loxapine (EMA-001115-PIP01-10) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.



European Medicines Agency decision

P/220/2011

of 30 September 2011

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for loxapine (EMEA-001115-PIP01-10) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the application submitted by Alexza UK Limited on 17 January 2011 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 12 August 2011, in accordance with Article 18 of Regulation (EC) No 1901/2006, and Article 21 of said Regulation and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver.
- (2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.
- (3) It is therefore appropriate to adopt a decision granting a deferral.
- (4) It is therefore appropriate to adopt a decision granting a waiver.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for loxapine, inhalation powder, pre-dispensed, inhalation use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for loxapine, inhalation powder, pre-dispensed, inhalation use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

A waiver for loxapine, inhalation powder, pre-dispensed, inhalation use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 4

This decision is addressed to Alexza UK Limited, 10 Station Road, RG9 1AY Henley-on-Thames, Oxfordshire, United Kingdom.

Done at London, 30 September 2011

For the European Medicines Agency
Andreas Pott
Acting Executive Director
(Signature on file)



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/PDCO/543928/2011

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral and a waiver

EMA-001115-PIP01-10

Scope of the application

Active substance(s):

Loxapine

Condition(s):

Treatment of schizophrenia

Treatment of bipolar disorder

Pharmaceutical form(s):

Inhalation powder, pre-dispensed

Route(s) of administration:

Inhalation use

Name/corporate name of the PIP applicant:

Alexza UK Limited

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Alexza UK Limited submitted for agreement to the European Medicines Agency on 17 January 2011 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

The procedure started on 23 February 2011.

Supplementary information was provided by the applicant on 24 May 2011. The applicant proposed modifications to the paediatric investigation plan.



Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to agree the paediatric investigation plan in accordance with Article 18 of said Regulation,
- to grant a deferral in accordance with Article 21 of said Regulation,
- to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(b) of said Regulation, on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified subset(s) of the paediatric population.

The Icelandic and the Norwegian Paediatric Committee members agree with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex(es) and appendix.

London, 12 August 2011

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman
(Signature on file)

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed Paediatric Investigation Plan

1. Waiver

1.1. Condition: Treatment of schizophrenia

The waiver applies to:

- All subsets of the paediatric population from birth to less than 12 years of age;
- for inhalation powder, pre-dispensed for inhalation use;
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s).

1.2. Condition: Treatment of bipolar disorder

The waiver applies to:

- All subsets of the paediatric population from birth to less than 10 years of age;
- for inhalation powder, pre-dispensed for inhalation use;
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s).

2. Paediatric Investigation Plan

2.1. Condition: Treatment of schizophrenia

2.1.1. Indication(s) targeted by the PIP

Rapid control of agitation in patients with schizophrenia.

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 12 to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Inhalation powder, pre-dispensed for inhalation use

2.1.4. Studies

Area	Number of studies	Description
Quality	0	Not applicable.
Non-clinical	1	Study 1: Single-dose inhalation developmental tolerability and toxicokinetic study in rats
Clinical	2	Study 2: Safety, tolerability, and pharmacokinetics of loxapine inhalation powder in children and adolescents with schizophrenia or bipolar I disorder Study 3: A multicenter, randomised, double-blind, placebo- and active-controlled efficacy and safety study of loxapine inhalation powder for the treatment of agitation in children and adolescents with schizophrenia or bipolar I disorder

2.2. Condition: Treatment of bipolar disorder

2.2.1. Indication(s) targeted by the PIP

Rapid control of agitation in patients with bipolar disorder.

2.2.2. Subset(s) of the paediatric population concerned by the paediatric development

From 10 to less than 18 years of age.

2.2.3. Pharmaceutical form(s)

Inhalation powder, pre-dispensed for inhalation use.

2.2.4. Studies

Same as the studies specified for the condition Treatment of schizophrenia.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By June 2014
Deferral for one or more studies contained in the paediatric investigation plan:	Yes